Noile-Immune Biotech Inc.
TTSE:4893Total Valuation
JPYAs of June 30, 2026, Noile-Immune Biotech Inc. carries a market capitalization of 5.25B, placing it among publicly traded companies globally. Its enterprise value stands at 1.71B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 5.25B |
| Enterprise Value | 1.71B |
Important Dates
Noile-Immune Biotech Inc.'s next confirmed earnings release is scheduled for November 13, 2026.
| Earnings Date | 11/13/2026 |
Share Statistics
As of June 30, 2026, Noile-Immune Biotech Inc. has 43.40M shares outstanding.
| Shares Outstanding | 43.40M |
Valuation Ratios
These figures are as of June 30, 2026.
| PB Ratio | 1.47 |
| P/TBV Ratio | 1.47 |
Financial Position
As of June 30, 2026, Noile-Immune Biotech Inc. maintains a current ratio of 42.73, meaning it holds 42.7x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 42.73 |
| Quick Ratio | 41.65 |
Financial Efficiency
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 23.50 |
Stock Price Statistics
JPYAs of the close on October 22, 2026, Noile-Immune Biotech Inc.'s stock has declined approximately 46.06% over the past 52 weeks. The 50-day moving average sits at 128.26, while the 200-day moving average is 139.32.
| 52-Week Price Change | -46.06% |
| 50-Day Moving Average | 128.26 |
| 200-Day Moving Average | 139.32 |
Balance Sheet
JPYThese figures are as of June 30, 2026. Total book value stands at 3.57B, with working capital of 3.55B providing operational flexibility.
| Cash & Cash Equivalents | 3.54B |
| Net Debt | -3.54B |
| Equity (Book Value) | 3.57B |
| Book Value Per Share | 82.36 |
| Working Capital | 3.55B |